Generate Biomedicines (NASDAQ:GENB) Now Covered by Morgan Stanley

Investment analysts at Morgan Stanley started coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research report issued on Tuesday. The brokerage set an “overweight” rating and a $20.00 price target on the stock. Morgan Stanley’s target price indicates a potential upside of 59.74% from the stock’s previous close.

Several other research analysts have also recently issued reports on GENB. Wall Street Zen raised Generate Biomedicines to a “hold” rating in a research note on Saturday, March 14th. The Goldman Sachs Group initiated coverage on Generate Biomedicines in a research report on Tuesday. They set a “buy” rating and a $26.00 target price for the company. Guggenheim assumed coverage on Generate Biomedicines in a research report on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. Finally, Cantor Fitzgerald assumed coverage on Generate Biomedicines in a research note on Tuesday. They set an “overweight” rating on the stock. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.00.

Generate Biomedicines Trading Up 2.0%

GENB stock opened at $12.52 on Tuesday. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.